(XZEM) MSCI Emerging Markets ESG 1C - Overview
Etf: Emerging, Markets, ESG, Stocks, USD
| Risk 5d forecast | |
|---|---|
| Volatility | 15.1% |
| Relative Tail Risk | -2.16% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.73 |
| Alpha | 10.77 |
| Character TTM | |
|---|---|
| Beta | 0.249 |
| Beta Downside | 0.520 |
| Drawdowns 3y | |
|---|---|
| Max DD | 20.90% |
| CAGR/Max DD | 0.57 |
Description: XZEM MSCI Emerging Markets ESG 1C January 14, 2026
The Xtrackers MSCI Emerging Markets ESG UCITS ETF 1C (ticker XZEM) tracks the Morningstar Emerging Markets Total Market ESG (NR) USD Index, offering investors exposure to a broad basket of equities across developing economies while applying an ESG screening overlay.
Key ETF characteristics (as of the latest fact-sheet):
- Issuer: Xtrackers (Deutsche Bank), domicile Germany, listed on XETRA.
- Category: Global Emerging Markets Equity – UCITS-compliant.
- Expense ratio: 0.20% p.a., which is competitive relative to peer ETFs that typically charge 0.25-0.35%.
- Assets under management (AUM): roughly €1.2 bn, indicating solid investor interest but still room for scale.
- Top sector weights: Financials (~25%), Consumer Staples (~15%), and Information Technology (~12%), reflecting the composition of the underlying MSCI EM ESG index.
From a macro perspective, the fund’s performance is driven by the growth trajectory of emerging markets, which are collectively expected to contribute about 55% of global GDP growth through 2030, powered by younger demographics, rising urbanization, and higher commodity demand. However, downside risks include currency volatility, policy tightening in China, and ESG-related re-weighting that may under-represent high-carbon sectors.
For a deeper dive into the fund’s risk-adjusted returns and ESG scoring methodology, you might find ValueRay’s analytical dashboard useful.
What is the price of XZEM shares?
Over the past week, the price has changed by +0.74%, over one month by +2.63%, over three months by +5.81% and over the past year by +18.77%.
Is XZEM a buy, sell or hold?
What are the forecasts/targets for the XZEM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 59.6 | 3.8% |
XZEM Fundamental Data Overview February 04, 2026
Revenue TTM = 0.0 EUR
EBIT TTM = 0.0 EUR
EBITDA TTM = 0.0 EUR
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 1.63b EUR (1.63b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 1.63b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 1.63b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 25.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 6.83% (E(1.63b)/V(1.63b) * Re(6.83%) + (debt-free company))
Discount Rate = 6.83% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Fair Price DCF = unknown (Cash Flow 0.0)